INTRODUCTION: The objectives of this study were to determine the economic, clinical, and quality-of-life outcomes associated with @entity1037 treatment in @entity1 diagnosed with @entity162 . METHODS: @entity1 with a diagnosis of @entity162 with @entity162 or mixed episodes were enrolled in a randomized controlled trial. The study design comprised a 3-week acute phase followed by a 49-week open label extension. In the open label extension, the use of @entity1091 and @entity905 was permitted for @entity1 who experienced breakthrough symptoms. Clinical, economic, and quality-of-life outcomes of treatment were assessed. RESULTS: During the acute phase, @entity1037 @entity1 experienced a statistically significant greater mean improvement from baseline on the Y-MRS total score compared to the placebo @entity1 . In the open label extension, @entity1 experienced a statistically significant mean change of 11.8 units on the Y-MRS from the end of the acute phase. When compared to costs incurred in the previous 12 months of therapy, @entity1 experienced savings of almost  900 per month during the 49 weeks of @entity1037 therapy. These cost savings were largely driven by reductions in in- @entity1 costs during the open label extension. Health-related quality of life improvements measured by the SF-36 were seen on several dimensions both in the 3-week acute phase as well as in the 49-week open label extension. CONCLUSION: From a clinical, economic, and quality-of-life outcomes standpoint, @entity1037 had a significant impact in the treatment of @entity162 , and could be considered a cost-effective treatment option for use in this population if these findings are extrapolated to non-clinical trial populations.

Economic, clinical, and quality-of-life outcomes associated with XXXX treatment in @entity162 . Results from a randomized controlled trial.

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'patient'] @entity162 :: ('MESH:D001714', 'Disease') :: ['manic', 'bipolar I disorder', 'mania'] @entity905 :: ('MESH:D005473', 'Chemical') :: ['fluoxetine'] @entity1091 :: ('MESH:D008094', 'Chemical') :: ['lithium'] @entity1037 :: ('MESH:C076029', 'Chemical') :: ['olanzapine']
@entity1037 :: (MESH:C076029,Chemical) :: ['olanzapine']
